Drugs / HZ/su
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05047770 | Oct 2021 → Aug 2022 | herpes zoster | GlaxoSmithKline | Completed | Met primary |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2023-08-23 | GlaxoSmithKline | Results New Shingrix data demonstrate 100% vaccine efficacy in the prevention of shingles in adults aged 50 and over in China gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced positive results from the first-ever efficacy trial of Shingrix (Recombinant Zoster Vaccine or RZV) in China. |
| 2023-06-26 | GlaxoSmithKline | Regulatory Japan’s Ministry of Health, Labour and Welfare approves Shingrix for the prevention of shingles in at-risk adults aged 18 and over gsk.com ↗ |
| 2022-10-19 | GlaxoSmithKline | Results New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over gsk.com ↗
GSK plc (LSE/NYSE: GSK) today announced positive interim results from the ZOSTER-049 extension study showing that overall Shingrix (Zoster Vaccine Recombinant, Adjuvanted) can provide at least a decade of protection against shingles (herpes zoster) after initial vaccination. |
| 2017-10-25 | GlaxoSmithKline | Regulatory CDC’s Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up gsk.com ↗
Herpes Zoster subunit vaccine (Shingrix) is preferred over Zoster Vaccine Live (Zostavax) for the prevention of herpes zoster and related complications. |
| 2017-06-21 | GlaxoSmithKline | Results GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC’s Advisory Meeting gsk.com ↗
The study met its primary objective of demonstrating non-inferior immune response (i.e. antibody concentrations). |
| 2016-09-14 | GlaxoSmithKline | Results GSK’s candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM gsk.com ↗
A pooled analysis of data from both trials showed the vaccine demonstrated 91% efficacy against shingles (95% confidence interval: 86-95%) in adults aged 70 years and older compared to placebo1. |
| 2015-04-28 | GlaxoSmithKline | Results GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2 which does not diminish in the age groups studied gsk.com ↗
Analysis of the primary endpoint showed that a two-dose schedule of HZ/su reduced the risk of herpes zoster by 97.2% (95% confidence interval [CI] 93.7-99.0) in adults aged 50 years and older compared to placebo. |
| 2014-12-18 | GlaxoSmithKline | Results Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint gsk.com ↗
Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2 per cent in adults aged 50 years and older compared to placebo. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HZ/su | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05047770 ↗ |
| Route | Intramuscular | “2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose.” NCT05047770 ↗ |